Redefining extended-spectrum β-lactamases: balancing science and clinical need - authors' response

Giske, C. G., Sundsfjord, A. S., Kahlmeter, G., Woodford, N., Nordmann, P., Paterson, D. L., Canton, R. and Walsh, Timothy Rutland ORCID: https://orcid.org/0000-0003-4315-4096 2009. Redefining extended-spectrum β-lactamases: balancing science and clinical need - authors' response. Journal of Antimicrobial Chemotherapy 64 (1) , pp. 213-215. 10.1093/jac/dkp143

Full text not available from this repository.

Abstract

Recently, we proposed a modified β-lactamase scheme for extended-spectrum β-lactamases (ESBLs) in recognition of the fact that this term is no longer sufficient to encapsulate accurately all β-lactamases possessing extended-spectrum activity and therefore requires refining.1 Our proposal was mainly based on a clinical perspective emphasizing the need for smooth communication between various groups of healthcare professionals. Accepting that such a proposal would be controversial, nonetheless we do not seek to polarize the ‘β-lactamase community’, but to stimulate dialogue on the merits of existing classifications and to explore necessary improvements. In reply to our proposal, Bush et al.2 raise a number of points that we wish to respond to:

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	ESBLs, AmpC, carbapenemases
Publisher:	Oxford University Press
ISSN:	0305-7453
Last Modified:	20 Oct 2022 07:54
URI:	https://orca.cardiff.ac.uk/id/eprint/26850

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item